Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Collaboration Agreement (Details)

v3.20.2
Collaboration and Research Arrangements - Collaboration Agreement (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2019
Jan. 31, 2018
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Deferred revenue         $ 26,822,000   $ 26,822,000   $ 28,378,000
Deferred revenue, net of current portion         16,743,000   16,743,000   22,639,000
GBT                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Deferred revenue         19,001,000   19,001,000   20,000,000
GBT | Collaboration Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Initial period of research term 3 years                
Additional extension period for research term upon mutual agreement 1 year                
Upfront payment receivable $ 20,000,000.0                
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000,000.0                
Agreement termination, prior written notice if notice delivered during the research term 9 months                
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 90 days                
Total transaction price $ 60,000,000.0           60,000,000.0    
Upfront non-refundable and non-creditable payment 20,000,000.0                
Reimbursable costs $ 40,000,000.0                
Change in total transaction price             0    
Revenue recognized         2,500,000   4,700,000    
Deferred revenue         19,000,000.0   19,000,000.0    
Deferred revenue, short-term         6,900,000   6,900,000    
Deferred revenue, net of current portion         12,100,000   12,100,000    
GBT | Collaboration Agreement | Maximum [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Period of extension of initial research term 2 years                
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000,000.0                
Incyte                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Revenue recognized         700,000 $ 500,000 900,000 $ 900,000  
Deferred revenue         7,821,000   7,821,000   $ 8,378,000
Deferred revenue, short-term         3,200,000   3,200,000    
Deferred revenue, net of current portion         $ 4,600,000   4,600,000    
Incyte | Collaboration Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Total transaction price   $ 12,300,000 $ 12,800,000       12,800,000    
Upfront non-refundable and non-creditable payment             2,500,000    
Up-front consideration       $ 10,000,000.0          
Up-front consideration, cash       2,500,000          
Up-front consideration, pre-paid research funding       $ 7,500,000          
Prepaid research amount             7,500,000    
Premium paid on equity investment             2,300,000    
Collaboration agreement additional consideration incurred             $ 500,000